Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALMS Alumis Inc.

盘前交易 07-17 06:32:01 EDT

11.09

-0.20

-1.77%

最高11.49	最低10.58	成交量11.13万
今开11.49	昨收11.29	日振幅8.10%
总市值5.75亿	流通市值2.33亿	总股本5,184万
成交额122.90万	换手率0.53%	流通股本2,097万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":11.09,"timestamp":1721160000000,"preClose":11.29,"halted":0,"volume":111277,"delay":0,"floatShares":20966511,"shares":51844729,"eps":0,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.2,"latestTime":"07-17 06:32:01 EDT","open":11.49,"high":11.49,"low":10.575,"amount":1229018.188698,"amplitude":0.081045,"askPrice":12.32,"askSize":100,"bidPrice":4.44,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721223000000},"adr":0,"listingDate":1719547200000,"adjPreClose":11.09,"postHourTrading":{"tag":"盘后","latestPrice":11.09,"preClose":11.09,"latestTime":"18:20 EDT","volume":11,"amount":126.17,"timestamp":1721168440057},"volumeRatio":0.6677696451879954},"requestUrl":"/m/hq/s/ALMS","defaultTab":"news","newsList":[{"id":"2450026060","title":"BUZZ-Alumis 在上市后首个交易日收阳一天后重拾跌势","url":"https://stock-news.laohu8.com/highlight/detail?id=2450026060","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450026060?lang=zh_cn&edition=full","pubTime":"2024-07-09 22:44","pubTimestamp":1720536269,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    7月9日 - ** 生物制药公司Alumis  的股价在上个月首次公开募股（(link)）后下跌1.3%。** 公司正在开发解决免疫功能障碍的口服疗法** 由于IPO市场复苏乏力，ALMS是少数未能吸引投资者的公司之一** 截至上一交易日收盘，ALMS公司的股价较首次公开募股价格下跌了20%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007","BUZZ"],"gpt_icon":0},{"id":"2449339750","title":"医药公司Alumis纳斯达克上市：市值6亿美元 核心管线来自海思科","url":"https://stock-news.laohu8.com/highlight/detail?id=2449339750","media":"雷递网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449339750?lang=zh_cn&edition=full","pubTime":"2024-07-07 20:26","pubTimestamp":1720355214,"startTime":"0","endTime":"0","summary":"生物医药公司Alumis(NASDAQ:ALMS)日前在美国纳斯达克上市，发行价为16美元，发行1310万股。截至目前，Alumis股价为11.45美元，较发行价下跌28%；以当前股价计算，公司市值为5.94亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240707/6385598080893417401265999.jpg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240707/6385598080893417401265999.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.leinews.com/n27109/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4007","MNQmain","QID","NDX","ARTL",".IXIC","03086","TQQQ","SQQQ","BK1147","PSQ","NQmain","QLD","ALMS","QQQ"],"gpt_icon":0},{"id":"2448943123","title":"BUZZ-Alumis 在纳斯达克首次上市后无精打采，全天下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2448943123","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448943123?lang=zh_cn&edition=full","pubTime":"2024-07-02 01:25","pubTimestamp":1719854752,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    7月1日 - ** 生物制药公司 Alumis   在纳斯达克 (link) 首秀不温不火，上市第二天股价下跌 3** 在Reddit (link)   等公司重新崛起后，新股销售热情减退，股价较16美元的IPO价格下跌了20%。** ALMS 在其规模缩小的首次公开募股中筹集了 2.1 亿美元，而此前设定的目标是至少 2.82 亿美元。** ALMS希望开发口服疗法来解决免疫功能紊乱问题，但尚未产生任何收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQ","QID","TQQQ","BUZZ",".IXIC","NQmain","MNQmain","PSQ","SQQQ","ARTL","BK4007","NDX","QLD","ALMS"],"gpt_icon":0},{"id":"2447638134","title":"Alumis 首次登陆纳斯达克股价下跌近 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2447638134","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447638134?lang=zh_cn&edition=full","pubTime":"2024-06-29 00:41","pubTimestamp":1719592918,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月28日 - 生物制药公司Alumis   周五在纳斯达克首次公开招股(IPO)，开盘价比首次公开招股价低近16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","NDX","NQmain","QID","MNQmain",".IXIC","QQQ","SQQQ","ALMS","QLD","ARTL","PSQ","BK4007"],"gpt_icon":0},{"id":"2446289500","title":"生物技术公司Alumis(ALMS.US)今晚上市 定价为每股16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446289500","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446289500?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:24","pubTimestamp":1719581044,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开发口服疗法的临床阶段生物制药公司Alumis将以每股16.00美元的价格首次发行1312.5万股股票，将于6月28日在纳斯达克交易，股票代码为“ALMS”。Alumis今天还宣布，公司已同意以每股16.00美元的价格向现有投资者之一AyurMaya Capital Management Fund,LP同时私募增售250万股。首次公开发行和同时进行的私募发行的总筹资额预计为2.5亿美元。据悉，承销商拥有30天的超额配售权，最多可额外购买1,968,750股。摩根士丹利、Leerink Partners、Cantor Fitzgerald 和Guggenheim Securities担任此次交易的联合账簿管理人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALMS"],"gpt_icon":0},{"id":"2446541791","title":"更新版 1-疗法开发商 Alumis 在美国上市，估值约 9.02 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446541791","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446541791?lang=zh_cn&edition=full","pubTime":"2024-06-28 12:41","pubTimestamp":1719549661,"startTime":"0","endTime":"0","summary":"     路透6月28日 -    Alumis   将其美国首次公开募股的定价定为每股16美元，这是其价格区间的下限，估值约为9.02亿美元。Alumis 公司的前身是 Esker Therapeutics 公司，在获得 2.59 亿美元的 C 轮融资三个多月后，它将继续推进上市计划。该公司致力于开发解决免疫功能障碍的口服疗法，其目标是筹集约2.1亿美元资金。Alumis 预计将在纳斯达克上市，股票代码为 \"ALMS\"。摩根士丹利、Leerink Partners、Cantor Fitzgerald 和古根海姆证券是此次发行的承销商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2446952549","title":"疗法开发商 Alumis 在美国的首次公开募股定价为每股 16 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446952549","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446952549?lang=zh_cn&edition=full","pubTime":"2024-06-28 12:12","pubTimestamp":1719547947,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月28日 - 治疗开发商Alumis   周四晚些时候表示，公司已将首次公开发行的1310万股股票定价为每股16美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2446670688","title":"生物技术公司Alumis(ALMS.US)IPO定价16-18美元/股 拟筹资3亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446670688","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446670688?lang=zh_cn&edition=full","pubTime":"2024-06-25 15:10","pubTimestamp":1719299453,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，位于加利福尼亚州南旧金山的生物技术公司Alumis周一宣布了首次公开募股的条款。该公司计划以每股16至18美元的价格发行1,770万股股票，预计筹资总额达3亿美元。据了解，Alumis的研发管线中，目前最受关注的是两种酪氨酸激酶2抑制剂。公司计划在2024年下半年启动ESK-001针对中度至重度斑块状银屑病的第三阶段关键性试验。Alumis成立于2021年，该公司计划在纳斯达克交易所上市，股票代码为ALMS。该公司预计将在2024年6月24日当周定价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALMS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":-0.0562},{"period":"1month","weight":-0.3069},{"period":"ytd","weight":-0.3069}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1285},{"period":"6month","weight":0.1855},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.1884}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alumis Inc.于2021年1月29日注册成立，为特拉华州公司。他们是一家临床阶段的生物制药公司，最初专注于开发两种酪氨酸激酶2（TYK2）抑制剂：ESK-001，一种他们正在开发的第二代抑制剂，以实现最大的靶向抑制，以及A-005，一种中枢神经系统渗透分子。该公司的使命是通过靶向治疗取代广泛的免疫抑制，显著改善患者的生活。","exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}